FIG. 3.
(a) Effect of abacavir on the spread of HIV strain IIIB. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 IIIB cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the calculated constant infusion level of a 500-mg dose (0.42 μg/ml abacavir) (▴). The second was exposed to a simulated 500-mg q24h dose (•) using the computer-driven pump to simulate an oral dose. The third was an untreated unit (▪) that was continuously exposed to medium without drug. Samples were taken at the indicated time points, and p24 was measured as indicated. (b) Effect of abacavir on the spread of HIV strain MN. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 MN cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the calculated constant infusion level of a 500-mg dose (0.42 μg/ml abacavir) (▴). The second was exposed to a simulated 500-mg q24h dose (•) using the computer-driven pump to simulate an oral dose. The third was an untreated unit (▪) that was continuously exposed to medium without drug. Samples were taken at the indicated time points and p24 was measured as indicated. (c) Effect of the schedule on the ability of the same total exposure of abacavir (AUC24 = 10.0838 mg·h/liter) on the spread of HIV strain MN. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 MN cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the 250-mg q12 dose (▪). The second was exposed to a simulated 500-mg q24h dose (▴) using the computer-driven pumps to simulate an oral dose. The third was an untreated unit (•) that was continuously exposed to medium without drug. Samples were taken at the indicated time points, and p24 was measured as indicated.